View Author
platelet transfusion patient reference count study platelet transfusion group treatment platelet support increment platelet transfusions period blood cycle support event number posttransfusion component platelet dose 24- difference product sample platelet components cycle 1 treatment groups 109/ system organ class buffy analysis regression analysis buffy coats hemorrhagic count increment center effect inactivation reference platelet transfusions symptom cancer antibody plasma population reference patients table platelet doses efficacy score regression reference platelet pools on-protocol transfusions response system 5 days method reference platelet products cell lines assay duration 8 transfusions interval class hemostatic study center test group test pools thrombocytopenia on-protocol thrombocytopenic patients baxter healthcare corporation single-donor posttransfusion platelet counts leukocyte process covariate platelet additive solution pathogen 56-
2 Most Recent Publications
|
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines
(Article)
Boonstra, J.J. Marion, R. van Schrump, D.S. Klimstra, D.S. Tang, L.H. Eshleman, J.R. Alvarez, H. Shimada, Y. Dekken, H. van Tilanus, H.W. Dinjens, W.N.M. Beer, D.G. Lin, L. Chaves, P. Ribeiro, C. Pereira, A.D. Roque, L. Darnton, S.J. Altorki, N.K. |
2010-02-01
|
|
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial
(Article)
Rhenen, D.J. van Marblie, S. Corash, L. Flament, J. Ljungman, P. Kluter, H. Vermeij, H. Mayaudon, V. Lin, L. Kappers-Klunne, M.C. Buchholz, D. Greef, G.E. de Laforet, M. Davis, K. Conlan, M. Lioure, B. Gulliksson, H. Cazenave, J.P. Metzel, P. Pamphilon, D. |
2003-03-15
|